H. pylori Reprograms Stomach Cells Into a Fetal-Like State, Study Finds

Helicobacter pylori (H. pylori) infects an estimated 44 percent of adults worldwide, according to a recent global analysis, and it is the single strongest known risk factor for stomach cancer. A study published in Nature Communications now shows the bacterium does something more specific than simply inflaming the stomach lining: it appears to reset gastric gland cells back to a state that resembles the developing stomach in a fetus, and the trigger for that reset comes from the tissue surrounding the glands, not from the infected cells themselves. For anyone who has been told they carry H. pylori, or who is trying to understand why a decades old infection can eventually turn into something serious, the finding fills in a missing step in that timeline.

Key Takeaways

• H. pylori infection does not just make stomach gland cells multiply faster. In mice, it switches on a broad embryonic gene program, a "fetal-like" regenerative state normally silent in adult tissue.
• The switch is thrown by immune cells, not the infected gland cells themselves: invading neutrophils and macrophages release IL-1β, which activates a COX2/PGE2 signal in the surrounding connective tissue, which then flips on the growth protein YAP in nearby stomach cells.
• The core experiments were done in genetically engineered mice and lab-grown mouse tissue. Human relevance so far comes from matching gene activity in existing human tissue datasets, not a clinical trial.
• The same COX2/PGE2 chemistry identified here is already linked to gastric cancer risk in people, part of why the mechanism matters even though it has not been tested as a treatment target.

H. pylori Pushes Stomach Glands Into an Embryonic State

Researchers found that H. pylori infection triggers gastric gland cells to activate a fetal-like transcriptional program, a set of genes normally active only during stomach development before birth and then switched off for life. The team traced this to loss of BMP signaling (bone morphogenetic protein, a chemical signal that normally restrains stomach stem cell growth) in the gastric lining. Using mice engineered to lack the BMP receptor (Bmpr1a) specifically in stomach stem cells, the researchers reproduced the same gland overgrowth and fetal-like gene activity seen in H. pylori infected mice, even with zero bacteria present, confirming that losing BMP signaling, not the bacteria directly, is what flips the switch. This kind of embryonic reversion echoes a broader pattern of fetal-like regeneration already documented elsewhere in the gut after injury.

Chronic Gastritis and Gastric Cancer Are the Stakes

H. pylori infection is already established as the leading cause of chronic gastritis (long-term stomach lining inflammation) and the strongest known risk factor for non-cardia gastric cancer, one of the deadliest cancers worldwide. The new study helps explain the biology behind that risk: the fetal-like reprogramming described here has previously been linked to precancerous changes such as hyperplasia (excess tissue growth) and metaplasia (stomach cells changing into an abnormal cell type), recognized stepping stones toward gastric cancer.

Engineered Mice, Organoids, and Human Data Cross-Checks

To pin down the mechanism, the researchers combined several tools. They infected mice with the PMSS1 strain of H. pylori for two months, long enough to produce gastritis and early precancerous changes similar to what shows up in chronically infected people. They also built "assembloids," lab-grown 3D structures that combine stomach epithelial cells with the stromal (connective tissue) cells that normally surround them, to watch the two cell types signal to each other directly. Critically, the team created a second mouse line lacking the IL-1 receptor specifically in stromal cells; when that receptor was removed, mice largely failed to activate the fetal-like YAP response and developed less gland overgrowth after infection, even though they ended up more heavily colonized by bacteria because their antimicrobial defenses were blunted along with it. Finally, the researchers checked whether the same signaling genes (IL1R1, PTGS2, PTGES) show up in existing human stomach single-cell datasets, and found the same fibroblast subtypes expressing them in human tissue as in the mouse model.

What This Could Mean If You Have (or Had) H. pylori

For someone managing a confirmed H. pylori infection, this study does not change what to do today: testing and antibiotic eradication therapy remain the established path. A meta-analysis of randomized trials covering more than 100,000 people found that eradicating the infection cuts gastric cancer risk by roughly 39 percent. What the new work adds is a more precise picture of why the infection is dangerous when it lingers: it is not the bacteria alone but the layered immune response, immune cells releasing IL-1β, connective tissue responding with COX2 and PGE2, and gland cells reverting to an embryonic growth pattern, that appears to drive the tissue changes tied to cancer risk. That is also not a reason to start taking NSAIDs (nonsteroidal anti-inflammatory drugs like ibuprofen or aspirin, which block COX enzymes) on your own; the study did not test that, and NSAIDs carry their own risk of stomach irritation and bleeding, especially with an active H. pylori infection.

Where the Evidence Still Falls Short

The causal experiments here, the genetic knockouts, the organoid and assembloid systems, the pharmacological blocking of the PGE2 receptor, were all done in mice and mouse-derived lab models, not in people. The human portion of the study is a correlational check: matching gene-expression patterns in previously published human single-cell datasets, not a new human trial or a biopsy comparison of infected versus uninfected patients. Whether interfering with this exact IL-1β to COX2 to YAP pathway would meaningfully lower gastric cancer risk in humans, and whether it could be done safely, remains untested.

What Comes Next

The authors frame their findings as an explanation for something researchers already suspected from other angles: COX2 is already known to be elevated in gastric cancer and premalignant lesions, and clinical studies have linked H. pylori eradication to falling COX2 activity. This study supplies a mechanistic link between those separate observations, running from bacterial infection through immune signaling to a specific stromal-to-epithelial handoff. A logical next step, though not yet reported in this paper, would be testing whether narrowly targeting this pathway, rather than broadly inhibiting COX2, which carries its own cardiovascular and bleeding risks, can block the fetal-like reprogramming without disabling the antimicrobial defenses that depend on the same immune signal.

Common Questions

Should I take ibuprofen or aspirin to lower my stomach cancer risk if I have H. pylori? No. This study did not test NSAIDs in people, and NSAIDs carry real risks of stomach irritation and bleeding, which matters more with an active H. pylori infection. Antibiotic eradication therapy, prescribed by a doctor, remains the established approach.

Is it dangerous for stomach cells to look "fetal-like"? Not automatically. This kind of regenerative state is a normal short-term repair response seen elsewhere in the gut after injury. The concern in this study is what happens when infection keeps that state switched on for months or years instead of letting it resolve.

How did researchers study this without testing on humans? They used mice genetically engineered to lack specific signaling receptors, lab-grown mouse stomach organoids, and "assembloid" co-culture systems combining stomach cell types, then cross-checked the genes involved against existing human tissue datasets to see if the same pattern shows up in people.

Does having H. pylori mean I will get stomach cancer? No. Most people with H. pylori never develop gastric cancer. This study describes one biological pathway that appears to contribute to precancerous tissue changes during chronic infection, not a guaranteed outcome.

References

1. Giulia Beccaceci, Stefanie Müllerke, Hilmar Berger, et al. (2026). Helicobacter pylori triggers gastric mucosal remodeling toward a fetal-like transcriptional program via stromal IL-1β signaling. Nature Communications. https://doi.org/10.1038/s41467-026-77520-1
2. Maryam Shirani, Reza Pakzad, Mohammad Hossein Haddadi, et al. (2023). The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-023-08504-5
3. Sara Viragova, Dong Li, Ophir D. Klein (2024). Activation of fetal-like molecular programs during regeneration in the intestine and beyond. Cell Stem Cell. https://doi.org/10.1016/j.stem.2024.05.009
4. Zhouhan Wu, Yi Tang, Meiwen Tang, Zhoutong Wu, Yonghui Xu (2025). The relationship between the eradication of Helicobacter pylori and the occurrence of stomach cancer: an updated meta-analysis and systemic review. BMC Gastroenterology. https://doi.org/10.1186/s12876-025-03886-z